MannKind rallies on Afrezza optimism

Shares of MannKind (MNKD +5%) are strong to start the week.

SA contributor Maredin Capital Advisors — who has "owned shares for the better part of six years and endured quite a bit of volatility in the process" — likens Afrezza's market potential to Lipitor and Plavix and says FDA approval is "a low hurdle at this juncture."

The author goes on to say that Afrezza "will likely become the dominant player in the $44B insulin market due to its unique pharmacokinetics/efficacy and convenience." The article appeared elsewhere last month.

Also bullish is SA contributor Stock Whisper, who highlights the company's presentation at the Piper Jaffray healthcare conference.

From other sites
Comments (2)
  • NewTampaResident
    , contributor
    Comments (85) | Send Message
    Agree with Maredin's positive assessment of Alfreeza. I have no doubt the needle injected liquid insulin industry has been trying to derail Alfreeza since it's inception. From inane incorrect comments by unsubstantiated posters on Yahoo message boards to late pop up websites like SummerStreet and even Cramer, the negative comments continue about Alfreeza in spit of the successful clinical trials date earlier this year. I think Alfreeza will be a market dominate drug like Viagra. I look for the pps to be near $30 after FDA approval in April and over $200 @ sh by 2018.
    6 Jan 2014, 06:09 PM Reply Like
  • miriam ledwith
    , contributor
    Comments (292) | Send Message
    There's a lot of supportive infrastructure that's needed with insulin injections: the alcohol swabs, the materials that go into making the pens, the syringes for coverage [when pen dosing not paid for buy insurance], the sheathed disposable needles for the pens, the bio hazard containers: it's a whole little industry behind each injection that would be displaced by an inhaled form of insulin. mnl
    8 Jan 2014, 05:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs